Kopran Ltd Stock Price Today (NSE: KOPRAN)

Kopran Ltd

195.920.04 (0.02%)
Market Closed

Fundamental Score

...

Kopran Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis

Kopran Ltd share price today is 195.92, down 0.02% on NSE/BSE as of 18 June 2026. Kopran Ltd (KOPRAN) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of 678.69 (Cr). The 52-week high for KOPRAN share price is 219.00 and the 52-week low is 107.00. At a P/E ratio of 38.54x, KOPRAN is currently trading above its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 7.64% and a debt-to-equity ratio of 0.31.

Kopran Ltd Share Price Chart — NSE/BSE Historical Performance

No data
High
203.50
Low
147.65
Volume
12.7L
Change
+20.83%

Kopran Ltd share price chart: 20.83% return over the past month. 52-week high ₹219.00, 52-week low ₹107.00.

Kopran Ltd — Last 10 Trading Days

DateOpenHighLowCloseVolume
186.17199.90186.17195.924.90L (Cr)
197.40202.00195.96195.961.66L (Cr)
194.50219.00194.05206.2738.55L (Cr)
193.58193.58193.58193.580.00 (Cr)
192.81202.80191.50193.5814.24L (Cr)
193.90203.50189.20193.9142.07L (Cr)
165.63195.81165.20188.48119.37L (Cr)
167.00168.81162.00163.182.82L (Cr)
169.00175.49166.10167.256.73L (Cr)
169.70174.25166.20167.1712.68L (Cr)

Kopran Ltd — Last 12 Months Price History

MonthOpenHighLowCloseChange
197.40202.00186.17195.92-0.75%
164.63219.00147.65206.27+25.29%
111.50166.60110.24164.63+47.65%
128.00130.58107.00108.04-15.59%
125.00146.83119.81131.83+5.46%
151.40157.85125.27128.05-15.42%
133.50159.89127.52150.43+12.68%
163.60167.95123.11134.49-17.79%
174.36184.00164.61165.37-5.16%
152.14186.90151.52174.36+14.60%
160.01165.80151.39152.13-4.92%
189.55189.80160.50161.11-15.00%

Returns & Performance

Poor

Return on Equity (ROE)

7.64%

Profit generated per ₹1 of shareholder equity

Poor

Return on Capital (ROCE)

9.75%

Returns generated on total capital deployed

Excellent

Oper. Profit Margin (5Y Avg)

13.33%

Average operating profit margin over 5 years

Good

Dividend Yield

2.13%

Annual dividend as % of current share price

Kopran Ltd Valuation Check

Poor

Price to Earnings (P/E)

38.54x

Share price ÷ earnings per share. Lower = cheaper

Poor

Industry Avg P/E

31.77x

Average P/E of all peers in this sector

Market-cap Classification
Small-cap
Higher growth potential with higher volatility.

Shareholding Pattern

Excellent

Promoter Holding

44.42%

% shares held by company founders/management

Poor

FII Holding

0.60%

% shares held by foreign institutional investors

Poor

DII Holding

0.00%

% held by domestic mutual funds, LIC, banks

Excellent

Promoter Pledged %

0.00%

% of promoter shares pledged as collateral — lower is safer

Growth Engine

Poor

Profit Growth (Quarterly YoY)

-234.42%

Net profit growth vs same quarter last year

Poor

Revenue Growth (Quarterly YoY)

-22.20%

Revenue growth vs same quarter last year

Good

Revenue Growth (5-Year CAGR)

11.86%

Compounded annual revenue growth over 5 years

Poor

EPS Growth (5-Year CAGR)

9.95%

Earnings per share growth over 5 years

Good

Net Profit Growth (5-Year CAGR)

12.38%

Compounded annual net profit growth over 5 years

Balance Sheet Health

Excellent

Debt to Equity Ratio

0.31x

Total debt ÷ equity. Below 0.5 = financially healthy

Excellent

Interest Coverage Ratio

3.70x

EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably

Free Cash Flow (5-Year Total)

-90.37 (Cr)

Cash left after capex over 5 years. Positive = self-funded growth

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Kopran Ltd Fundamental Analysis & Valuation Benchmarking

Educational evaluation of KOPRAN across key market metrics for learning purposes.

Positive Indicators

1 factors identified

Zero Share Pledging Risk

Observation: No promoter shares pledged as collateral.

Analysis: Absence of share pledging eliminates potential forced-selling pressure.

Risk Factors

6 factors identified

Below-Average Return on Equity (7.64%)

Observation: Returns on equity are below industry benchmarks.

Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.

Suboptimal ROCE (9.75%)

Observation: Returns on capital employed are below expectations.

Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.

Profit Decline Concern (-234.42%)

Observation: Significant year-over-year profit contraction observed.

Analysis: Declining profitability requires investigation into underlying causes.

Revenue Contraction (-22.20%)

Observation: Sales decline may indicate market challenges or competitive pressures.

Analysis: Negative revenue growth requires analysis of market conditions.

Negative Free Cash Flow (₹-90.37 Cr over 5Y)

Observation: Cash outflows exceed inflows.

Analysis: Negative FCF requires analysis of capital expenditure cycle.

Limited Institutional Interest (FII+DII: 0.60%)

Observation: Low institutional participation may affect liquidity.

Analysis: Limited institutional interest may indicate size constraints or visibility issues.

Kopran Ltd vs Pharmaceuticals Peers

Peer Comparison - Pharmaceuticals

Compare Kopran Ltd with 10 other companies in the same sector

11 companies
Company Info
Fundamental
Valuation
Profitability
Financial Health
Growth
Dividend
Company
Company name
Score
Bull Run comprehensive fundamental score based on 20+ metrics
Price
Current trading price of the stock
Market Cap
Total value of all shares in the market
P/E
Price per share divided by earnings per share
ROE
Net income divided by shareholder equity
ROCE
Earnings before interest and tax divided by capital employed
Debt/Eq
Total debt divided by total equity
Profit 5Y
Average annual profit growth over 5 years
Sales 5Y
Average annual sales growth over 5 years
Dividend
Annual dividend per share divided by price per share
31.8/100
196
₹678.69
38.5
Average
7.64%
Poor
9.75%
Poor
0.3
Excellent
12.38%
Good
11.86%
Good
2.13%
65.2/100
1844
₹433738.68
37.6
Average
16.86%
Good
20.21%
Excellent
0.1
Excellent
23.78%
Excellent
9.87%
Good
0.89%
67.9/100
6798
₹170445.88
68.6
Average
15.35%
Good
20.44%
Excellent
0.0
Excellent
10.41%
Good
11.65%
Good
0.47%
65.3/100
4538
₹126430.62
58.4
Average
26.52%
Excellent
27.05%
Excellent
0.3
Excellent
13.84%
Good
7.72%
Good
0.86%
Cipla Ltd...
CIPLA500087
59/100
1418
₹123059.76
22.6
Average
17.77%
Good
22.72%
Excellent
0.0
Excellent
28.68%
Excellent
9.97%
Good
0.85%
59.2/100
1319
₹105224.96
18.2
Average
17.96%
Good
22.69%
Excellent
0.2
Excellent
22.28%
Excellent
13.26%
Good
0.63%
Lupin Ltd...
LUPIN500257
66.7/100
2276
₹95148.15
22.0
Average
20.62%
Excellent
21.30%
Excellent
0.3
Excellent
54.88%
Excellent
8.11%
Good
0.58%
68.7/100
957
₹94253.78
18.7
Average
21.21%
Excellent
24.31%
Excellent
0.4
Excellent
25.92%
Excellent
10.27%
Good
1.17%
50.6/100
2420
₹92012.53
52.6
Average
14.68%
Average
15.98%
Good
0.6
Good
11.73%
Good
15.79%
Excellent
0.04%
28.8/100
1436
₹70798.69
20.7
Average
11.08%
Average
14.18%
Average
0.2
Excellent
3.87%
Average
6.55%
Good
0.33%
59.5/100
5452
₹67075.29
28.5
Average
19.39%
Good
20.38%
Excellent
0.2
Excellent
13.93%
Good
9.21%
Good
0.80%

Kopran Ltd PE Ratio History

Historical price-to-earnings ratio for KOPRAN — last 5 years

YearEPS (₹)Price (₹)P/E Ratio
FY 20257.99₹150.4318.8x
FY 202410.55₹211.7820.1x
FY 20235.65₹241.2542.7x
FY 202213.77₹150.8511x

P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.

Kopran Ltd Dividend History

Annual cash dividends paid by KOPRAN — dividend yield 2.13%

Financial YearDividends Paid (₹ Cr)
FY 202514.46 Cr
FY 202414.46 Cr
FY 202314.46 Cr
FY 20226.49 Cr

Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.

Kopran Ltd Quarterly Performance

Latest quarterly metrics for KOPRAN — revenue growth and profit growth vs same quarter last year

Revenue Growth (YoY)

-22.20%

Latest quarter vs same quarter previous year

Net Profit Growth (YoY)

-234.42%

Latest quarter net profit vs same quarter previous year

5-Year Revenue CAGR

11.86%

Compounded annual revenue growth over 5 years

5-Year Profit CAGR

12.38%

Compounded annual net profit growth over 5 years

Kopran Ltd Technical Indicators

SMA 50, SMA 200, RSI and volume signals for KOPRAN — calculated from daily price history

68RSI 14
Neutral — RSI 68

Momentum is balanced — neither overbought nor oversold.

SMA 50
149
▲ Price above SMA 50 — Short-term bullish
SMA 200
150
▲ Price above SMA 200 — Long-term uptrend
30-Day Avg Volume
1044K shares/day
Average daily traded volume over last 30 trading sessions

Technical indicators are for educational purposes only. Not investment advice.

Kopran Ltd Financial Statements

Annual income statement, balance sheet and cash flow for Kopran Ltd (KOPRAN) — sourced from NSE/BSE filings.

Loading Financial Statements...

Fetching financial data for Kopran Ltd

About KOPRAN (Kopran Ltd)

Kopran Ltd is a pharmaceutical entity forging a path in the global landscape, distinguished by its comprehensive approach to healthcare solutions. The company deftly navigates the ...spectrum from foundational active pharmaceutical ingredients (APIs) to the creation of diverse finished dosage forms. With a commitment to accessibility, Kopran addresses a wide range of medical needs, crafting formulations that include both branded innovations and widely accessible generic alternatives. This dedication to providing diverse options allows them to cater to varied patient populations across both India and the global stage, reinforcing their commitment to widespread health accessibility. The company's manufacturing prowess is evident in its extensive product portfolio, encompassing an array of dosage forms designed to meet diverse patient requirements. From easily administered tablets and capsules to convenient syrups and suspensions, and even advanced injectables and specialized dry powder formulations, Kopran demonstrates a versatility that sets it apart. This breadth of capabilities allows them to deliver therapeutic solutions that are tailored to specific conditions and patient preferences, ensuring optimal treatment outcomes. The meticulous attention to detail in each stage of production underscores their commitment to quality and patient well-being. Kopran's therapeutic focus encompasses a broad spectrum of prevalent health challenges. Their product offerings include critical medications across several important categories, such as macrolides for managing infections, potent antibacterials to combat resistant strains, and anticonvulsants for neurological care. Additionally, they provide essential anti-hypertensive drugs for cardiovascular health, and effective anti-helminth medications for parasite control. This strategic targeting of key therapeutic areas demonstrates Kopran's dedication to addressing pressing global health needs, contributing to the overall improvement of patient care and well-being across diverse communities.

Company Details

Symbol:KOPRAN
Industry:Pharmaceuticals
Sector:Pharmaceuticals

Key Leadership

Mr. Surendra Shrikrishna Somani B.Com.
Executive Vice Chairman & MD
Mr. Basant Kumar Soni
Chief Financial Officer
Mr. Sunil Radheyshyam Sodhani
Company Secretary & Compliance Officer

Corporate Events

Recent
Ex-Dividend Date

KOPRAN Share Price: Frequently Asked Questions

What is the current share price of Kopran Ltd?

Kopran Ltd (KOPRAN) trades at ₹195.92 on NSE and BSE. Market cap ₹678.69 (Cr). Educational data only.

What is the P/E ratio of Kopran Ltd?

Kopran Ltd has a P/E of 38.54x vs industry average 31.77x.

What is the Bull Run score for Kopran Ltd?

Kopran Ltd has a Bull Run score of 31.8/100 based on 25+ financial parameters.

Does Kopran Ltd pay dividends?

Kopran Ltd has a dividend yield of 2.13%. Past dividends don't guarantee future payments.

What is the ROE of Kopran Ltd?

Kopran Ltd has ROE of 7.64%. Higher ROE indicates better use of shareholder equity.

What is the debt-to-equity ratio of Kopran Ltd?

Kopran Ltd has debt-to-equity of 0.31.

Is Kopran Ltd a good investment?

Bull Run gives Kopran Ltd a score of 31.8/100. This is not investment advice — consult a SEBI-registered advisor.